Search Results

The last external expert assessment was undertaken during the 2021/22 financial year and the Prior to giving their directors' declaration in respect of the physical risks identified during that risk assessment have now half-year and annual financial statements, the Board requires been integrated into the existing enterprise risk management the Chief Executive Officer and the Chief Financial Officer to processes in accordance with the Enterprise Risk Management each sign a written declaration to the Board, to the effect that, Framework.

CSL engages stakeholders and periodically undertakes a formal materiality assessment process to understand our relevant sustainability-related topics.

11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL's second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results.

CSL's Code of Responsible Business Practices guides our interactions with stakeholders and sets expectations for responsible business conduct.

CSL Vifor expects to launch FILSPARI in the first European markets in the second half of 2024.

Iron deficiency affects about half of the patients suffering from chronic kidney disease.

In Canada, Ferinject ® is commercialized through CSL Behring Canada, Inc., with availability expected in the second half of 2024.

The number of Rights granted is equivalent to the fee sacrificed divided by the prevailing market price of CSL shares at that time Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

The U.S. Food and Drug Administration’s new ARC program aims to enable coordination, collaboration and research support.

Prior to giving their directors' declaration in respect of the Key business/industry risks and financial risks, including any annual and half-year financial statements, the Board requires applicable environmental and social sustainability risks and the Chief Executive Officer and the Chief Financial Officer CSL's material exposure and actions to manage these risks to each sign a written declaration to the Board, to the effect are set out in sections 4, 8 and 9 of the 2023 Annual Report that, in their opinion, the financial records of the entity have available on CSL.com (Investors).